Global top pharmaceutical companies by oncology market share 2017 and 2024
Swiss -based company Roche was the global leader based on oncology market share in 2017 and is forecasted to maintain this position until 2024. However, it is expected that the market share will decrease dramatically from the current 26 percent to under 12 percent by 2024. The main reason for this development is that competitors like Celgene, Bristol Myers-Squibb, and Johnson and Johnson will dominate with their key oncology products by that year. Additionally, several of Roche’s blockbuster oncologic drugs will face sales erosion due to biosimilar competition.
Oncology market overview
The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.
The rise of immune-oncology
The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.
Oncology market overview
The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.
The rise of immune-oncology
The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.
